-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce Biosciences Publishes First Clinical Manuscript On Multi-Pill Abuse Resistance Overdose Protection Technology

Benzinga·03/03/2026 13:03:48
Listen to the news

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics designed to minimize risk of abuse and overdose, today announced the publication of the first clinical manuscript describing its MPAR® (Multi-Pill Abuse Resistance) overdose protection technology.

The paper, titled "Formulation and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug with Oral Opioid Overdose Protection," appears online in the Journal of Opioid Management Jan/Feb 2026 issue.